Click here to learn about Academy events, publications and initiatives around COVID-19.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

Support The World's Smartest Network
×

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

DONATE
This site uses cookies.
Learn more.

×

This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.

Mary Collins

Mary Collins

Provost

Okinawa Institute of Science and Technology Graduate University

Prof. Collins studied Biochemistry at Cambridge University then moved to the University of London at the Imperial Cancer Research Fund for her PhD. Collins worked as a post-doctoral fellow on molecular immunology at University College London, then the Whitehead Institute, MIT. She started her own group at the Institute of Cancer Research in 1987. Collins moved to University College London as Professor of Immunology in 1997. From 2005 to 2015 she was Director of the Britain’s Medical Research Council Centre for Medical Molecular Virology. After heading the Division of Infection and Immunity at University College London for 10 years, Collins was Dean of the Faculty of Life Sciences at University College London from 2009 until 2014. In September 2014 Prof. Collins took up a secondment at the National Institute for Biological Standards and Control to head a new Division of Advanced Therapies.